Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Regulatory Post-Marketing Surveillance(PMS) Study for Lucentis®(Ranibizumab) in Patients With Retinopathy of Prematurity

NCT05304949 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT05304949
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05304949 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Regulatory Post-Marketing Surveillance(PMS) Study for Lucentis®(Ranibizumab) in Patients With Retinopathy of Prematurity
Lead sponsor
Novartis Pharmaceuticals
Phase
Observational
Overall status
Completed
Start date
June 22, 2022
Completion date
January 11, 2025
Enrollment
69 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

retinopathy of prematurity